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unrecognized stages. Many affected
travelers may not seek medical atten-
tion or may have received a wrong
diagnosis. Therefore, surveillance
based only on reported cases is likely
to underestimate the true incidence of
travel-associated R. africae infection.
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Catheter-related
Bacteremia and
Multidrug-resistant
Acinetobacter 
lwoffii 
To the Editor: Acinetobacter
species are ubiquitous in the environ-
ment. In recent years, some species,
particularly A. baumannii, have
emerged as important nosocomial
pathogens because of their persistence
in the hospital environment and broad
antimicrobial drug resistance patterns
(1,2). They are often associated with
clinical illness including bacteremia,
pneumonia, meningitis, peritonitis,
endocarditis, and infections of the uri-
nary tract and skin (3). These condi-
tions are more frequently found in
immunocompromised patients, in
those admitted to intensive care units,
or in those who have intravenous
catheters, and those who are receiving
mechanical ventilation (4,5). 
The role of A. baumannii in noso-
comial infections has been document-
ed (2), but the clinical effect of other
Acinetobacter species has not been
investigated. A. lwoffii (formerly A.
calcoaceticus var. lwoffii) is a com-
mensal organism of human skin,
oropharynx, and perineum that shows
tropism for urinary tract mucosa (6).
Few cases of A. lwoffii bacteremia
have been reported (3,5–7). We report
a 4-year (2002–2005) retrospective
study of 10 patients with A. lwoffii
bacteremia admitted to a 600-bed
teaching hospital in central Italy. 
All 10 patients were immunocom-
promised; 8 had used an intravascular
catheter (peripheral or central) and 2
had used a urinary catheter. Blood
cultures of the patients were analyzed
with the BacT/ALERT 3D system
(bioMérieux, Marcy l’Etoile, France).
Isolates were identified as A. lwoffii
by using the Vitek 2 system and the
API 20NE system (both from
bioMérieux). 
Susceptibilities of 10 A. lwoffii iso-
lates to 18 antimicrobial drugs were
determined by the broth microdilution
method, according to Clinical and
Laboratory Standards Institute (CLSI,
formerly NCCLS) guidelines (8). The
drugs tested were amikacin, ampi-
cillin-sulbactam, aztreonam, cefe-
pime, cefotaxime, ceftazidime, ceftri-
axone, ciprofloxacin, gentamicin,
imipenem, levofloxacin, meropenem,
ofloxacin, piperacillin, piperacillin-
tazobactam, tetracycline, tobramycin,
and trimethoprim-sulfamethoxazole.
MIC was defined as the lowest drug
concentration that prevented visible
bacterial growth. Interpretative crite-
ria for each drug tested were as in
CLSI guidelines (8). A. lwoffii resist-
ant to >4 classes of drugs were
defined as multidrug-resistant (MDR)
isolates.  
A. lwoffii isolates were genotyped
by pulsed-field gel electrophoresis
(PFGE) to determine their epidemio-
logic relatedness. Chromosomal DNA
was digested with SmaI (9) and ana-
lyzed with a CHEF DR II apparatus
(Bio-Rad Laboratories, Hercules, CA,
USA). PFGE patterns were classified
as identical, similar (differed by 1–3
bands), or distinct (differed by >4
bands) (10). 
Among the 10 A. lwoffii isolates, 6
were susceptible to all drugs except
cephalosporins (cefepime, cefo-
taxime, ceftazidime, and ceftriaxone)
and aztreonam. The other 4 isolates
were MDR: 3 were susceptible only to
imipenem (MICs 1–4 µg/mL),
meropenem (MICs 1–2 µg/mL), and
amikacin (MICs 2–4 µg/mL). The
fourth MDR strain was susceptible to
imipenem (MIC 2 µg/mL), meropen-
em (MIC 2 µg/mL), amikacin (MIC 4
µg/mL), and ciprofloxacin (MIC 1
µg/mL). Seven antimicrobial drug
resistance profiles were detected
(Table).
Macrorestriction analysis of the A.
lwoffii isolates identified 8 distinct
PFGE types. Two MDR strains
(strains 2 and 3 in the Table), which
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were isolated from patients in differ-
ent wards, and 2 non-MDR strains
(strains 8 and 9), which were isolated
from patients in the same ward, had
similar PFGE patterns and identical
resistance phenotypes. These findings
suggest nosocomial transmission.
Nine of the 10 patients survived after
catheter removal or treatment with
appropriate antimicrobial drugs.
These results confirm that catheter-
related A. lwoffii bacteremia in
immunocompromised hosts is associ-
ated with a low risk for death (4,6). 
This study identified A. lwoffii
MDR strains that cause bacteremia in
immunocompromised catheterized
patients. Our data are consistent with
those of previous reports on the role
of catheters as the principal source of
A. lwoffii infections.
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